Bimekizumab not checked
UCB Biopharma SRL · UCB4940
FollowEvery change as it happens, and a Monday email
Trials
9 active
42 in total · 14 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Bimekizumab will be administered at pre-specified timepoints.”In the company’s words, NCT06921850 on ClinicalTrials.gov
- Tested for
- Moderate to Severe Plaque Psoriasis (3 trials), Psoriatic Arthritis (3 trials), Hidradenitis Suppurativa (2 trials), Axial Spondyloarthritis (2 trials), Palmoplantar Pustulosis, Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis
- Main trialPhase 3
- “The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)”In the company’s words, NCT06921850 on ClinicalTrials.gov
- Other names
- BKZ · UCB4940 · Bimzelx
Other drugs for Moderate to Severe Plaque Psoriasis
- ZasocitinibTakeda · Phase 3
- TQH3906Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Phase 3
- PiclidenosonCan-Fite BioPharma · Phase 3
- Total coumarin creamPsoriasis Research Institute of Guangzhou · Phase 3
- RisankizumabAbbVie · Phase 3
- PonesimodVanda Pharmaceuticals · Actelion · Phase 3
Coming up7
- 21 DecPhase 3 trial completes · ClinicalTrials.gov
- 9 Mar 2027Phase 3 trial completes · ClinicalTrials.gov
- 27 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- 31 Dec 2027Phase 1 trial completes · ClinicalTrials.gov
- 12 Apr 2028Phase 3 trial completes · ClinicalTrials.gov
- 18 May 2028Phase 1 trial completes · ClinicalTrials.gov
- 21 Aug 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials42
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 21 Dec 2026 | A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa | |
| Phase 3Active, not recruiting | 9 Mar 2027 | A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis | |
| Phase 3Recruiting | 27 Dec 2027 | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis | |
| Phase 3Recruiting | 12 Apr 2028 | An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis | |
| Phase 3Active, not recruiting | 21 Aug 2028 | A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis | |
| Phase 1Recruiting | 31 Dec 2027 | A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) | |
| Phase 1Recruiting | 18 May 2028 | A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults | |
| Phase 3Completed | 28 Dec 2018 | A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis | |
| Phase 3Completed | 8 Jan 2019 | A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis | |
| Phase 3Completed | 7 Feb 2019 | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis | |
| Phase 3Completed | 12 Sep 2019 | A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis | |
| Phase 3Completed | 14 Jul 2020 | A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO) | |
| Phase 3Completed | 5 Nov 2020 | A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis | |
| Phase 3Completed | 17 Aug 2021 | A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis | |
| Phase 3Completed | 3 Sep 2021 | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis | |
| Phase 3Completed | 9 Nov 2021 | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa | |
| Phase 3Completed | 8 Dec 2021 | A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis | |
| Phase 3Completed | 7 Apr 2022 | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa | |
| Phase 3Completed | 29 Jun 2022 | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis | |
| Phase 3Completed | 5 Sep 2022 | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis | |
| Phase 3Completed | 14 Nov 2023 | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis | |
| Phase 3Completed | 5 Feb 2025 | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis | |
| Phase 3Completed | 6 Feb 2026 | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis | |
| Phase 3Completed | 26 May 2026 | A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis | |
| Phase 3Completed | 22 Jul 2026 | A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa | |
| Phase 3Completed | 9 Aug 2026 | A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis | |
| Phase 2Completed | Jun 2017 | Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis | |
| Phase 2Completed | Oct 2017 | A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis | |
| Phase 2Completed | Nov 2017 | A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis | |
| Phase 2Completed | 11 Dec 2017 | A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis | |
| Phase 2Completed | 25 Sep 2018 | A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis | |
| Phase 2Completed | 23 Nov 2018 | A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. | |
| Phase 2Completed | 6 Mar 2019 | A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis | |
| Phase 2Completed | 25 May 2020 | A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis | |
| Phase 2Completed | 29 Oct 2020 | A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis | |
| Phase 2Completed | 19 Oct 2022 | A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis | |
| Phase 2Completed | 12 Mar 2025 | A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis | |
| Phase 1Completed | 17 Jun 2016 | A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy Subjects | |
| Phase 1Terminated | 26 Apr 2021 | A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants | |
| Phase 1Completed | 9 Jan 2023 | A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants | |
| Phase 2Authorised | not given | EARLYPSO Early intervention in plaque psoriasis: is bimekizumab able to delay chronic inflammation? Prospective multicenter interventional study | |
| Phase 3Authorised | not given | Evaluation of the efficacy and safety of bimekizumab (BZK) or adalimumab (ADA) in the treatment of anterior chest wall pain associated with active axial spondyloarthritis refractory to NSAIDs with hypothesis of superiority of bimekizumab. Randomized, open-label, in parallel arms, head to head trial (ThoracSPA) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026